Novartis CEO Vas Narasimhan has projected that the pharmaceutical industry will witness tangible benefits from artificial intelligence within the next seven to ten years, as companies increasingly integrate advanced technologies across their operations. Speaking at the World Economic Forum in Davos, Narasimhan outlined the company's strategic approach to AI implementation and its broader growth objectives.

AI Innovation Hub in Hyderabad

The pharmaceutical giant has established a significant AI research and development presence in Hyderabad, where many of the company's leading scientists and engineers are spearheading innovation initiatives. According to Narasimhan, this facility serves as a crucial center for developing AI use cases aimed at modernizing the company's operations across research, development, and manufacturing processes.

Strategic Objectives and Cost Optimization

Narasimhan emphasized that Novartis has established ambitious goals for its workforce, with cost optimization serving as a key strategic objective. The company aims to leverage AI technology to accelerate medicine delivery processes, though the CEO noted that market development in India has not yet reached the desired pace.

The executive expressed satisfaction with the company's current employee numbers in India, indicating stability in the workforce structure as the organization pursues its AI-driven transformation initiatives.

Healthcare Access and Government Collaboration

Addressing healthcare accessibility in India, Narasimhan advocated for continued engagement with the Indian government to modernize the Ayushman Bharat system. This collaboration aims to enable wider access to innovative medicines for patients across the country, representing a significant opportunity for expanding healthcare reach.

Future Investment in Neuroscience

Looking toward future breakthroughs, Narasimhan highlighted neuroscience as a priority area for substantial investment. The company is focusing its research efforts on several critical areas:

• Neuromuscular diseases
• Huntington's disease
• Parkinson's disease
• Alzheimer's disease

These investments reflect Novartis' commitment to addressing some of the most challenging neurological conditions, potentially positioning the company at the forefront of breakthrough treatments in these therapeutic areas.

Novartis India Limited has officially communicated to BSE Limited regarding its upcoming Board of Directors meeting scheduled for January 28, 2026. The pharmaceutical company will consider and approve unaudited financial results for the quarter ended December 31, 2025, in compliance with regulatory requirements.

Board Meeting Schedule

The meeting has been scheduled pursuant to Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The board will convene on Wednesday with the primary agenda being the consideration and approval of Q3FY26 unaudited financial results.

Trading Window Closure

In connection with the upcoming board meeting, Novartis India Limited has announced the closure of its trading window for designated persons. The trading window will be closed from Thursday, January 1, 2026, affecting designated persons, insiders, connected persons, and their immediate relatives.

Official Communication Details

The formal communication was addressed to BSE Limited at Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai. The announcement was digitally signed by Chandni Maru, Company Secretary and Compliance Officer (M No. A60291), on December 30, 2025.

The company operates from its registered office at Inspire-BKC in Mumbai's Bandra Kurla Complex and maintains transparency through regular compliance with stock exchange regulations and stakeholder communication requirements.